rhPSMA-73 PET-MRI Imaging for Prostate Cancer Detection
EARLY_PHASE1
40
about 12 years
18+
Male only
1 site in IL
What this study is about
This trial is testing whether rhPSMA-73 PET-MRI imaging can help detect higher grade or stage prostate cancer in men who are candidates for active surveillance. It uses a radioactive drug to create detailed images of the prostate, which may be more effective than standard MRI scans in detecting certain types of prostate cancer.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Flotufolastat F-18 Gallium
- 2.Take Decipher Prostate Cancer Test
- 3.Undergo Biopsy of Prostate
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
flotufolastat (18F)
Primary: Radio-pathological correlation between positron emession tomography-magnetic resonance imaging (PET-MRI) and prostate biopsy or radical prostatectomy
Secondary: Incidence of Treatment-Related Adverse Events [Safety and Tolerability]
biopsy, imaging
Oncology